Untitled Document
 
 
  logo
sitemap enquiry contact  
 
 
    search  
 
 
 
 
  banner
1.Where is Bafna Pharma listed?
Bafna Pharma’s shares are listed in Bombay Stock Exchange ltd., Mumbai. (BSE Code: 532989)
2. Where are Bafna Pharma's corporate office, factories and research centers located?
Bafna Pharma’s corporate office is located at Chennai. The two factories are also located in Chennai one at Madhavaram and other at Grantylon. The R&D facility is also located at Grantylon.
3. What is the geographical spread of business?
The markets that the company serves are categorized as Exports and Domestic. The export market is in turn categorized as ‘Regulated market’ and ‘Non-regulated Market or Emerging Markets’. Bafna Pharma is present in regulated market of United Kingdom and Emerging Markets of Asia, Africa and Australia.
The total revenue achieved by the company is Rs. 7600 lakhs in FY ‘10. The company’s revenue from UK market is Rs. 891.3 lakhs during the year, a 700% growth compared to the revenue from the same market in FY 09. This signifies the shift in company’s focus towards high margin markets. The revenue share from this market has grown from about 2% of the total sales during FY ‘09 to 12% during FY ‘10.
The Company plans to maintain and grow on this high margin growth trajectory.
4. Please explain the services of Bafna Pharma’s recently launched R&D unit.
At present, the R&D unit established is focussed into development of formulations. The key services are
Product development of Generics drugs specially for regulated markets like Europe, US and Australia
Technical analysis of formulations
Product development for Domestic market
Dossier filing for both regulated and Non regulated markets
The company plans to hive off this unit to extend the services to other companies and to make the division a profit center.
5. How many factories does Bafna Pharma have? How many of them are EU - GMP, UK - MHRA, TGA Australia approved? Have any facility obtained USFDA approval?
Company has two manufacturing facilities in Chennai one at Madhavaram and Grantlyon.
The Madhavaram facility is earmarked to cater to the requirements of Domestic and non - regulated markets while the Grantlyon facility caters to the exports to regulated market.
The Grantylon facility specializes in manufacturing of Non-Betalactam products in solid oral dosage.
The facility is accredited with EU - GMP, UK - MHRA, TGA Australia approval.
No facility is USFDA approved as of now. But the company has plans to obtain US FDA approval also.
6. How much dividend has been paid by the company after it got listed in 2008?
The company has not paid any dividend as it plans to conserve the funds to support the working capital and capital expenditure requirements of the fast propelled growth.
 
 
photogallery
camera
 
newsatbafna
arrow more
  19.01.2011
  student
Udyog Rattan Award
Our Chairman & Managing Director Mr. Bafna Mahaveer Chand, has received "Udyog Rattan Award".
  19.01.2011
  home
IDMA Award
Received IDMA Quality Excellence Silver Award 2010 – in the category of Formulation Units.
 
Bafna Pharma
 
icon Profile
icon CMD Statement
icon Vision & Mission
icon Board of Directors
icon Management Profile
icon Accreditations & Awards
icon Life at Bafna
 
icon Domestic Marketing
icon International Marketing
icon International Export
icon Business Development
icon Quality Policies
 
icon Facility ‑ Madhavaram
icon Facility ‑ Grantlyon
icon R & D
icon Visual Gallery
 
icon Financials
icon Presentations
icon FAQ
icon Stock Price
icon Share Holding Pattern
icon Disclosure
icon Policies
icon Domestic
icon Exports
 
icon Press Release
icon Bafna in the news
 
icon Job openings
icon Apply now
 
icon Health Sense
icon Environment
icon Responsibility
 
 
mailus separator

telephone

sepearator sepearator sepearator sepearator
 
followus
chat   facebook   twitter